Financial News
All
Basic Materials
Communication Services
Consumer Cyclical
Consumer Defensive
Energy
Financial Services
Healthcare
Industrials
Real Estate
Technology
Utilities
Macro
All Sentiment
Bullish
Neutral
Bearish
679 articles
📰
Exicure, Inc. Reports Full Year 2025 Financial Results
<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"...
📰
Exicure, Inc. Reports Full Year 2025 Financial Results
Exicure, Inc. Reports Full Year 2025 Financial Results
📰
Exicure, Inc. Reports Full Year 2025 Financial Results
Exicure, Inc. Reports Full Year 2025 Financial Results
📰
Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ: RARE) Investors of the Upcoming April 6th Lead Plaintiff Deadline and Urges Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Ultragenyx (RARE) To Contact Him...
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results
LOS ANGELES, March 25, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage...
📰
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results
<p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml"...
📰
Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights
<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" />
<p...
📰
CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
<ul xmlns="http://www.w3.org/1999/xhtml" type="disc">
<li xmlns="http://www.w3.org/1999/xhtml"><b...
📰
Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
MINNEAPOLIS, March 25, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of...
📰
Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights
Dose escalation for NKX019 advanced to 4 billion cells per dose on days 0, 3 and 7 for a total of 12 billion cells per cycle
Initial clinical data...
📰
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" />
<p...
📰
Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights
SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing...
📰
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" />
<p...
📰
Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" />
<ul...
Strategic Collective Launches "Speak Your Way to Sales" to Dismantle the Referral-Only Glass Ceiling for Speakers
Women hold only 33% of keynote slots due to "referral-only" loops. Speak Your Way to Sales (Eaton Press) is a tactical roadmap from 10 leaders to...
📰
Portnoy Law Firm Announces Class Action on Behalf of Atara Biotherapeutics, Inc. Investors
<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" />
<p...
Cancer Drug Developer Nanobiotix Denies Any Active Takeover Process
Nanobiotix S.A. (NASDAQ:NBTX) shares are up on Wednesday as the company responds to recent media speculation regarding potential acquisition...
Cancer Drug Developer Nanobiotix Denies Any Active Takeover Process
Nanobiotix S.A. (NASDAQ:NBTX) shares are up on Wednesday as the company responds to recent media speculation regarding potential acquisition...
HIMS vs. DOCS: Which Digital Health Stock Offers Better Upside Now?
Hims & Hers and Doximity are taking different paths in digital health, but which stock offers stronger upside now? Let's dive in.
HIMS vs. DOCS: Which Digital Health Stock Offers Better Upside Now?
Hims & Hers and Doximity are taking different paths in digital health, but which stock offers stronger upside now? Let's dive in.
BTSG and the Shift to Home Care as Margins Expand in 2026
BTSG targets margin expansion in 2026 as home-care demand grows, but policy and pricing pressures could cloud revenue trends.
BTSG and the Shift to Home Care as Margins Expand in 2026
BTSG targets margin expansion in 2026 as home-care demand grows, but policy and pricing pressures could cloud revenue trends.
Is BrightSpring BTSG Stock Expensive at 24.5x Forward P/E?
BTSG trades at 24.5x forward earnings after strong 2025 results, but 2026 hinges on margin gains offsetting policy-driven revenue headwinds.
Is BrightSpring BTSG Stock Expensive at 24.5x Forward P/E?
BTSG trades at 24.5x forward earnings after strong 2025 results, but 2026 hinges on margin gains offsetting policy-driven revenue headwinds.
BTSG and the Shift to Home Care as Margins Expand in 2026
BTSG targets margin expansion in 2026 as home-care demand grows, but policy and pricing pressures could cloud revenue trends.
Is BrightSpring BTSG Stock Expensive at 24.5x Forward P/E?
BTSG trades at 24.5x forward earnings after strong 2025 results, but 2026 hinges on margin gains offsetting policy-driven revenue headwinds.
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
FMS eyes growth on value-based care surge and FME25+ savings, but regulatory headwinds, flat volumes and China weakness cloud outlook.
Forget Rockets — SpaceX Takes $20 Billion Telecom Giant Public
Everyone's going to call it the biggest initial public offering ever. They'll talk about rockets, Mars and Elon Musk. But they'll be...
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TMDX rides OCS adoption and strong fourth-quarter results, but margin pressure raises questions for investors.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TMDX rides OCS adoption and strong fourth-quarter results, but margin pressure raises questions for investors.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TMDX rides OCS adoption and strong fourth-quarter results, but margin pressure raises questions for investors.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TMDX rides OCS adoption and strong fourth-quarter results, but margin pressure raises questions for investors.
📰
So-Young (SY) Q4 2025 Earnings Call Transcript
Image source: The Motley Fool.March 25, 2026, 7:30 a.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading